Cystinosin, the lysosomal cystine exporter defective in cystinosis, is the founding member of a family of heptahelical membrane proteins related to bacteriorhodopsin and characterized by a duplicated motif termed the PQ loop. PQ-loop proteins are more frequent in eukaryotes than in prokaryotes; except for cystinosin, their molecular function remains elusive. In this study, we report that three yeast PQloop proteins of unknown function, Ypq1, Ypq2, and Ypq3, localize to the vacuolar membrane and are involved in homeostasis of cationic amino acids (CAAs). We also show that PQLC2, a mammalian PQ-loop protein closely related to yeast Ypq proteins, localizes to lysosomes and catalyzes a robust, electrogenic transport that is selective for CAAs and strongly activated at low extracytosolic pH. Heterologous expression of PQLC2 at the yeast vacuole rescues the resistance phenotype of an ypq2 mutant to canavanine, a toxic analog of arginine efficiently transported by PQLC2. Finally, PQLC2 transports a lysine-like mixed disulfide that serves as a chemical intermediate in cysteamine therapy of cystinosis, and PQLC2 gene silencing trapped this intermediate in cystinotic cells. We conclude that PQLC2 and Ypq1-3 proteins are lysosomal/vacuolar exporters of CAAs and suggest that small-molecule transport is a conserved feature of the PQloop protein family, in agreement with its distant similarity to SWEET sugar transporters and to the mitochondrial pyruvate carrier. The elucidation of PQLC2 function may help improve cysteamine therapy. It may also clarify the origin of CAA abnormalities in Batten disease.
lysosomal storage disease | secondary active transporter T he transport of solute across membranes is crucial to eukaryotic cell physiology, as illustrated in the human species by the existence of diverse diseases associated with defective transport (1) (2) (3) and the presence of ∼400 solute transporter genes grouped into 51 families in the human genome (www.bioparadigms.org/slc/ menu.asp) (4, 5) . However, this inventory is far from being complete, because the function of many putative transporters remains unknown and, for technical reasons, the repertoire of elucidated activities is biased in favor of cellular uptake at the expense of less tractable activities, such as cellular export or intracellular solute compartmentalization. For instance, most of the proteins responsible for the export of lysosomal catabolites remain unknown (3) , and the lysosomal chloride transporter, ClC-7, was functionally characterized (6, 7) long after its identification. Even a key protein, such as the pyruvate transporter that fuels mitochondria and links glycolysis to the citric acid cycle, has long remained elusive (8, 9) . A novel family of transporters that export sugars from plant and animal cells has also been only recently unveiled (10, 11) .
In this study, we focus on a poorly characterized, mostly eukaryotic protein family defined by cystinosin, the lysosomal cystine transporter defective in human cystinosis (12, 13) . This family [Pfam no. PF04193 (14) ; Transporter Classification Database no. 2.A.43.1.1 (15) ], is characterized by a seven-helix membrane topology, a distant relationship with bacteriorhodopsin, and the presence of a duplicated motif termed the "PQ loop" (16, 17) . Although the transport activity of cystinosin is well established (12, 18) and consistent with human pathological findings (19) , the PQ-loop protein family is usually absent from transporter inventories because the molecular activity of other PQ-loop proteins remains unknown. In a recent study, we showed that cystinosin has a proton/cystine symport activity and we identified the cystinecoupled proton-binding site (D305) underlying this symport within the second PQ loop (18) . Moreover, analysis of a large, diverse set of PQ-loop proteins revealed amino acid correlations between the two PQ-loop sequences. Taken together, these data suggested that PQ loops are key functional elements that probably interact with each other, and they raised the possibility that other PQ-loop proteins may transport solutes across membranes (18) .
In this study, we addressed this hypothesis and identified another PQ-loop amino acid transporter using yeast genetics and flux measurements in Xenopus oocytes. The function of this transporter in the lysosomal/vacuolar membrane of eukaryotic cells is conserved from yeast to mammals. Moreover, we show that the human transporter plays a key role in the treatment of cystinosis with the aminothiol drug cysteamine. Cystinosis is a rare autosomal recessive disease caused by loss-of-function mutations in the cystinosin gene, CTNS. As a consequence, large amounts of cystine accumulate in a patient's lysosomes and progressively impair the function of multiple organs, including the kidneys, endocrine glands, muscles, and CNS (13, 19) . Cysteamine depletes cystine from cystinotic lysosomes and, on lifelong treatment, alleviates symptoms. According to an early biochemical model (19, 20) , cysteamine reacts with lysosomal cystine and forms a chemical intermediate that leaves lysosomes through a distinct, unaffected transporter. Our study now provides molecular evidence for this model.
Results
Yeast Ypq1-3 Proteins Are Vacuolar Membrane Proteins Associated with Homeostasis of Cationic Amino Acids. Six PQ-loop proteins have been inventoried in the yeast Saccharomyces cerevisiae (21) . One of these proteins, Ers1, was reported to encode a functional homolog of human cystinosin (22) , with which it shares 28.7% identity. The function of the five other PQ-loop proteins is unknown. At least two of them, Yol092p and Ydr352p (hereafter called Ypq1 and Ypq2), were reported in proteomic and genome-scale protein localization studies to be located at the membrane of the vacuole, the lysosome of yeast (23, 24) . By colabeling with fluorescent FM4-64 dye, we observed that Ypq1-GFP and Ypq2-GFP fusion proteins are indeed located at the vacuolar membrane and found that the same is true for another member of the family, Ybr147p, hereafter called Ypq3 (Fig. 1A) . These three PQ-loop proteins might thus transport compounds across the vacuolar membrane.
Interestingly, the YPQ3 gene has been predicted by a recent bioinformatic analysis of promoter signatures (25) to be under the control of the Lys14 transcription factor. Lys14 activates expression of the lysine-repressible LYS genes involved in lysine biogenesis (26) , and its positive action is highly stimulated in cells lacking the Lys80/Mks1 regulatory protein (27) or when lysine biosynthetic enzymes encoded by the LYS20 and LYS21 genes are resistant to feedback inhibition (28) . We monitored expression driven by the upstream control region of the YPQ3 gene and confirmed that it is under the positive control of Lys14, repressed by excess lysine, and derepressed in lys80 and LYS20 fbr LYS21 fbr mutant cells (Fig. 1B) . This expression is similar to that of LYS9, a well-studied target gene of Lys14 (Fig. S1 ). The YPQ3 gene thus encodes a putative vacuolar membrane transporter repressed by excess lysine. Because lysine is stored at a high concentration in the yeast vacuole (29, 30) , Ypq3 might export lysine to the cytosol, with its expression being inhibited when lysine is abundant in the cytosol (Fig. 1C) . Because Ypq1 and Ypq2 are closely similar in sequence to Ypq3 (21) (Fig. 1G) , they might perform a similar transport function [i.e., catalyze export of other cationic amino acids (CAAs; arginine and/ or histidine) that are also highly concentrated in the vacuole] (29, 30) . We isolated ypq1Δ, ypq2Δ, and ypq3Δ mutant strains, as well as a triple ypq mutant, and tested their growth on various media containing toxic analogs of CAAs. These experiments revealed that the ypq2Δ mutant is resistant to canavanine (Fig. 1D) , a natural analog of arginine that is misincorporated into proteins and is highly toxic to diverse species, including yeast (31, 32) . The ypq1Δ mutant also displays resistance to canavanine, but to a lesser extent than the ypq2Δ strain (Fig. 1D) . A previous study reported that uptake of the three proteinogenic CAAs into the yeast vacuole is mediated by the Vba1, Vba2, and Vba3 transporters from the major facilitator superfamily (33) . In a triple vba mutant, the Ypq2-dependent canavanine resistance phenotype is abolished (Fig. 1E) . A tentative interpretation of these observations is that Ypq2 and, to a lesser extent, Ypq1 export canavanine (and presumably other CAAs) from the vacuole. In the ypq2 mutant, canavanine would thus be sequestered in the vacuolar lumen, reducing its toxicity, provided that its accumulation in the vacuole via the Vba proteins is normal (Fig. 1F) .
The canavanine resistance phenotypes of the ypq1 and ypq2 mutants, and the fact that the YPQ3 gene is repressed at the transcriptional level by excess lysine, thus demonstrated that Ypq1-3 proteins are involved in homeostasis of CAAs, present at high concentrations in the vacuole, presumably through a vacuolar export mechanism.
Mammalian Homolog PQLC2 Is a Resident Lysosomal Membrane Protein. Interestingly, mammalian genomes contain a gene, PQLC2, encoding a protein more closely related in sequence to yeast Ypq1-3 proteins than to cystinosin (Fig. 1G) . Like cystinosin and Ypq1-3, PQLC2 is predicted to possess seven transmembrane α-helices, with an ∼40-residue, N-glycosylated N terminus in the lysosomal lumen and a shorter, cytosolic C terminus. The two PQloop motifs cover the second and fifth transmembrane helices and their connecting cytosolic loops (Fig. 2C ).
Using a semiquantitative MS analysis of proteins in highly enriched lysosomal membranes from rat liver cells (34), we found that PQLC2 is present at the lysosomal membrane ( Fig. 2A) . A comprehensive description of the proteins identified in these lysosomal membranes will be provided elsewhere. The statistical significance of the association of PQLC2 with lysosomes was assessed by calculating for each identified protein a spectral index ranging from −1 to +1 for proteins exclusively detected in lysosome-depleted and lysosome-enriched fractions, respectively. This index combines the relative peptide abundance in tandem MS (MS/MS) spectra (spectral counts) and the number of samples with detectable peptides to provide an estimate of protein abundance (35) . Across three biological replicates, we detected three peptides matching the rat PQLC2 sequence. The spectral index value of PQLC2 (0.892) was high and similar to that of the late endosomal/lysosomal markers lysosome-associated membrane protein 1 (LAMP1; 0.755) and LAMP2 (0.748), but well above that of proteins from other organelles and the 5% confidence threshold (0.594) ( Fig. 2 B and C) .
To confirm the subcellular localization, we tagged rat PQLC2 with EGFP at its C terminus and expressed the fusion protein in HeLa cells. Under fluorescence deconvolution microscopy, PQLC2-EGFP displayed a punctate distribution that extensively overlapped with LAMP1 ( Fig. 2D) , thus confirming the proteomic data. Resident membrane proteins are targeted to lysosomes by virtue of short cytosolic motifs that interact with adaptor protein complexes. These adaptors, in turn, interact with protein coats that ensure cargo selection and vesicle formation in the endocytic pathway (36) . We thus scrutinized the PQLC2 sequence for potential sorting motifs and identified an evolutionarily conserved, dileucine-type consensus sequence (285-EREPLL-291) in the C terminus (Fig. 2C) . Mutation of the critical leucine pair of this motif (LL290/291AA mutation, hereafter referred to as LL/AA) dramatically redistributed PQLC2-EGFP in HeLa cells. In contrast to the WT protein, PQLC2-LL/AA-EGFP displayed a diffuse distribution across the cell, including microvilli, thus suggesting that the mutant has been misrouted to the plasma membrane (Fig. 2E) . Quantitative real-time RT-PCR assay showed that PQLC2 mRNA is expressed at roughly similar levels across mouse tissues (Fig. 2F ), thus suggesting a housekeeping function. We concluded that PQLC2 is a ubiquitous, resident membrane protein of the lysosome and that its lysosomal localization is primarily determined by a C-terminal, dileucine-type sorting motif.
PQLC2 Transports CAAs. The above yeast and mammalian data prompted us to examine whether PQLC2 is a CAA transporter. The LL/AA sorting mutant provided favorable conditions for testing this hypothesis because it allows replacing the poorly tractable lysosomal activity by a classic, whole-cell influx equivalent to lysosomal efflux. Several lysosomal transporters have been successfully characterized using this whole-cell approach (6, 12, 18, 37, 38) . In preliminary experiments, we expressed PQLC2-LL/AA-EGFP in HEK-293 cells and examined their ability to take up [
]Lys) from acidic extracellular medium (which is topologically equivalent to the lysosomal lumen in our assay). Interestingly, PQLC2-LL/AA-EGFP moderately increased the uptake of CAA relative to WT PQLC2 and mock-transfected cells (Fig. S2) . However, the PQLC2-dependent signal was low or undetected in some experiments, presumably because the strong endogenous uptake of CAAs into mammalian cells masked PQLC2 activity.
We thus chose Xenopus laevis oocytes as an alternative expression system owing to their low endogenous uptake of amino acids, including cationic ones. When cRNA-injected oocytes were observed under epifluorescence microscopy, PQLC2-LL/AA-EGFP displayed a robust fluorescence at the plasma membrane, whereas staining was intracellular with free EGFP or WT PQLC2-EGFP (Fig. 3A) (Fig. 3C) . It was also strongly pH-dependent, with no detectable activity at an extracellular pH ≥7.0 ( Fig. 3D and To characterize the substrate selectivity of PQLC2, we applied unlabeled amino acids (10 mM) simultaneously with [ ]Arg transport, whereas other compounds had no effect (Fig.  3F ). L-ornithine inhibited PQLC2 as efficiently as arginine and histidine, whereas L-citrulline had no effect, thus confirming the requirement for a positively charged side chain. Lysine was slightly less efficient than arginine and histidine. We concluded from the above data that PQLC2 is a pH gradient-driven transporter that displays marked selectivity for CAAs.
Electrophysiological Characterization of PQLC2. To characterize further the transport activity of PQLC2, we applied CAAs (10 mM) to voltage-clamped oocytes and recorded their currents at −40 mV and pH 5.0. Arginine, histidine, lysine, and ornithine, but not citrulline, evoked a robust inward current in PQLC2-LL/AA-EGFP oocytes (Fig. 4 A and B) . Non-CAAs had no effect on PQLC2-LL/ AA-EGFP oocytes, nor had CAAs applied to water-injected oocytes. PQLC2 transport activity is thus electrogenic, as might be expected from the positive charge of its small-molecule substrates. Mean steady-state current values of −237 ± 13, −246 ± 43, −299 ± 44, and −151 ± 12 nA were obtained with 10 mM arginine (n = 43 oocytes), lysine (n = 15 oocytes), histidine (n = 19 oocytes), and ornithine (n = 11 oocytes). When responses were normalized for each oocyte to the arginine signal, the first three compounds yielded identical responses (Fig. 4B) , suggesting that they are translocated with similar velocities. The PQLC2 evoked current was strongly activated in acidic media (Fig. 4C ). In agreement with the radiotracer flux data, application of increasing arginine concentrations showed that the steady-state evoked current follows MichaelisMenten kinetics (Fig. 4D) , with mean K m and maximal current intensity (I max ) values of 2.1 ± 0.2 mM and −212 ± 19 nA, respectively, at −40 mV and pH 5.0 (28 oocytes from four batches).
Early biochemical studies on isolated lysosomes reported that the lysosomal transport pathway for CAAs ("system c") is sensitive to analogs, such as N-α-methyl-L-arginine (NαΜe-Arg) and ε-Ntrimethyl-L-lysine (3Me-Lys), which are not, or are poorly, accepted by the plasma membrane pathway ("system y+") (39) . We thus tested whether these compounds (10 mM) interact with PQLC2. For comparison, the system y+ transporter CAT-1 was expressed in oocytes and assayed for [ (Fig. S4A ). Both analogs also evoked an inward current in PQLC2-LL/AA-EGFP oocytes, albeit to a lesser extent than L-arginine ( Fig. S4 B and C) . We concluded that the functional properties of PQLC2 resemble those reported for the native lysosomal transporter and that the methylated analogs are substrates, rather than inhibitors, of PQLC2. 
(11) localized to the peripheral membrane of the vacuole (Fig. 5A ) and restored canavanine sensitivity in ypq2 cells (Fig. 5B) . Ypq2 is thus a functional ortholog of PQLC2. According to our working hypothesis (Fig. 1F) , vacuolar export of canavanine by PQLC2 may underpin its canavanine-sensitizing effect. To test this prediction, we applied canavanine to voltage-clamped PQLC2-LL/AA-EGFP oocytes and found, indeed, that the toxic analog elicits a robust inward current (Fig. 5C ). Paired experiments with increasing concentrations of arginine and canavanine revealed that the toxic analog is translocated by PQLC2 with a lesser affinity (K m = 5.6 ± 0.2 mM) but a higher capacity (I max = −596 ± 64 nA, n = 8 oocytes) than arginine (K m = 2.5 ± 0.2 mM, I max = −430 ± 46 nA) (Fig. 5 D and E) . This efficient transport of canavanine implies that overexpression of PQLC2 should increase the canavanine-toarginine ratio in the cytosol, in agreement with the observed drugsensitization phenotype. These data show that the molecular function of PQLC2 is conserved among eukaryotes, and suggest that Ypq2 and Ypq1 are similarly able to export canavanine (and presumably other CAAs) from the yeast vacuole. Conversely, the lack of the canavaninesensitivity phenotype in ypq3 yeasts suggests that Ypq3 does not transport this analog, possibly because evolutionary pressures have narrowed its substrate selectivity toward lysine.
Role of PQLC2 in Cysteamine Therapy of Cystinosis. Cysteamine therapy remains the most effective treatment for cystinosis (40) (41) (42) . The current model, based on early biochemical data (20, 43) , posits that the compound enters the lysosome and condenses with lysosomal cystine, thus generating a cysteaminecysteine mixed disulfide (MxD) that resembles lysine (Fig. 6A) . MxD is then exported from the lysosome through the system c CAA pathway (20) . The identification of PQLC2 as a lysosomal CAA transporter thus prompted us to examine its potential role in this cystine-depleting mechanism.
MxD (10 mM) efficiently inhibited [ 3 H]Arg transport by PQLC2 (Fig. 3F) . It also evoked a robust inward current in voltage-clamped PQLC2-LL/AA-EGFP oocytes (Fig. 6B) , showing that it is translocated by the lysosomal transporter. Paired application of increasing MxD and arginine concentrations at −40 mV and pH 5.0 showed that MxD is transported as rapidly as arginine with an affinity only twofold lower (Fig. 6C) . Mean I max values of −246 ± 24 nA and −305 ± 20 nA and mean K m values of 6.7 ± 0.7 mM and 3.4 ± 0.3 mM were obtained for MxD and arginine, respectively (five oocytes from two batches). We concluded that MxD is an efficient substrate of PQLC2.
We thus performed gene silencing on human cystinotic fibroblasts to test the role of PQLC2 in cysteamine therapy. Application of two different PQLC2 siRNAs [ON-TARGETplus (Dharmacon) reagent no. J-020760-18 or no. J-020760-19 (hereafter named no. 18 and no. 19)] efficiently and durably reduced the PQLC2 mRNA level in human cystinotic fibroblasts (Fig. 6D) . After two rounds of transfection, siRNAs no. 18 and no. 19 decreased the PQLC2 mRNA level, on average, to 39 ± 8% and 18 ± 3% of the untreated cell level, respectively, whereas a control (luciferase-targeted) siRNA had no effect (112 ± 8%, eight independent transfections). Due to the lack of good antibodies, we used an in situ functional assay based on lysine methyl ester to assess the impact of gene silencing at the protein level. When amino acid methyl esters are applied to intact cells, a significant proportion is converted to amino acid within the lysosome due to the high esterase activity of this organelle relative to other cell compartments (44) (Fig. 6E) (Fig.  6F) . We concluded that gene silencing significantly decreases endogenous PQLC2 activity and, consequently, increases retention of [ 3 H]Lys in the protected lysosomal environment. Finally, we transfected normal and cystinotic human fibroblasts with the siRNAs and tested their response to cysteamine. After gene silencing, cells were treated or not treated with cysteamine and cellular levels of cystine and MxD were measured by liquid chromatography (LC)-MS/MS. PQLC2 gene silencing specifically and dramatically increased the level of MxD in cysteamine-treated cystinotic cells (Fig. 6G) , with mean ratios of 15 ± 6-fold and 7.6 ± 2.1-fold relative to untreated cells for siRNA no. 18 and no. 19, respectively (three independent experiments). Only part (∼10%) of the initial cystine was "trapped" as MxD by the combined siRNA and cysteamine treatments (compare plots in Fig. 6G ), in agreement with the presence of residual PQLC2 activity after gene silencing (Fig. 6F, Right) . PQLC2-targeted siRNAs, but not a control siRNA, also exacerbated cystine storage in patient cells (Fig. 6G) for an unknown reason. However, this increase in cystine was limited (2.06 ± 0.16-fold and 2.12 ± 0.11-fold relative to untreated cells for siRNA no. 18 and no. 19, respectively; n = 3), and thus could not account for the increase in MxD after the cysteamine treatment. We concluded that PQLC2 exports MxD from cystinotic lysosomes and, consequently, plays a key role in the cystinedepleting effect of cysteamine.
Discussion
In this study, we characterized a set of heptahelical PQ-loop proteins and elucidated their molecular function using a combination of yeast genetics and flux measurement studies. In addition, we show that PQLC2 plays a key role in the cystine-depleting mechanism underlying cysteamine therapy of cystinosis. Mammalian PQLC2 and its yeast homologs Ypq1-3 localize to animal lysosomes and fungal vacuoles, respectively. Using a mutant construct misrouted to the plasma membrane, we clearly established that PQLC2 is able to export CAAs from acidic compartments. PQLC2 transport activity is strongly activated at low extracytosolic pH values, and it shows narrow selectivity for cationic side chains because it recognizes arginine, but not its neutral analog citrulline, as well as lysine and histidine among proteinogenic amino acids. It may be noted that the guanidinooxy group of L-canavanine, which is also efficiently translocated, has a pK a of 7.0 (45) in contrast to the side chain pK a of 12.5 for arginine. Canavanine is thus partially charged in neutral compartments. However, it is fully protonated in the lysosomal/vacuolar lumen and under the conditions of our transport assay (pH 5.0). To compare the properties of PQLC2 with those of the native transporter from lysosomes (system c), we took advantage of the discriminating effect of natural (3Me-Lys) and synthetic (NαΜe-Arg) methylated analogs relative to CAA transport at the plasma membrane (39) . In agreement with the earlier study, these compounds strongly interacted with PQLC2, but not, or more weakly, with the plasma membrane transporter CAT-1. Therefore, PQLC2 should play a major role in recycling CAAs generated in lysosomes and autolysosomes into the metabolic network. Because PQLC2 is also able to transport ornithine and 3Me-Lys, this cellular role probably extends to the modified amino acids issued from the degradation of methylated and ornithylated proteins. The precise transport mechanism of PQLC2 remains unclear because attempts to measure the charge/substrate coupling ratio by applying [ 3 H]Arg to voltage-clamped oocytes yielded variable results across oocyte batches. It is thus unknown whether the transport current recorded in PQLC2 oocytes is exclusively carried by CAAs (uniport mechanism) or shared by the CAA substrate with an inorganic ion (for instance, H + /CAA symport). This issue thus deserves further investigation. It is, however, noteworthy that the two PQ loops of PQLC2 harbor neutral side chains (W and M, respectively, in mammals) at the position equivalent to the substrate-coupled, proton-binding site of cystinosin (18) , but this does not exclude the existence of a protonbinding site elsewhere in PQLC2.
Our study also provides indirect evidence that yeast Ypq1 and Ypq2 proteins similarly act as vacuolar CAA exporters because (i) their genetic inactivation induces a canavanine-resistance phenotype that requires the vacuolar CAA importers Vba1-3 and (ii) heterologous expression of PQLC2 at the vacuolar membrane functionally complements the ypq2 mutation. The simplest explanation for these data is that the broadly specific Vba transporters (33) accumulate canavanine into the vacuole, thus reducing its cytosolic availability, whereas, in contrast, Ypq1 and Ypq2 export this toxic CAA from the vacuole (Fig. 1F) , as does PQLC2 (Fig. 5 C-E). Because canavanine naturally occurs solely in leguminous plants and their predators, a reasonable interpretation is that Ypq1 and Ypq2 also export proteinogenic CAAs from the vacuole under physiological conditions. The evidence supporting a similar role (presumably restricted to lysine) for Ypq3 is more indirect and based on the coordinated transcriptional regulation of the YPQ3 gene and those encoding lysine biosynthesis enzymes, thus suggesting a common role in the cytosolic availability of lysine.
In contrast to these conclusions, a previous study had suggested that the Schizosaccharomyces pombe homolog Stm1, which shares 36% and 28% sequence identity with S. cerevisiae Ypq1 and mammalian PQLC2, respectively, acts as a G protein-coupled receptor (GPCR) that inhibits vegetative cell growth and induces sporulation in response to nitrogen starvation (46) . However, mechanistic evidence for a GPCR function of Stm1 is weak. The conclusion that it physically interacts with the GTPase Gpa2 was based on the use of protein fragments in two-hybrid and pull-down assays suitable for soluble proteins, but not membrane proteins, and the argument that a reversed stretch of the Stm1 sequence is homologous to a motif found in known yeast GPCRs is evidently untenable. Therefore, fission yeast Stm1 may act as a vacuolar CAA exporter similar to its budding yeast homologs, a role consistent with the fact that STM1 transcription is induced under nitrogen, but not glucose starvation (46) .
The existence of another small-molecule transporter in the cystinosin protein family strongly suggests that membrane transport is a conserved functional feature of PQ-loop proteins, in agreement with our previous demonstration that PQ loops have a functional significance in the case of cystinosin (18) . For another heptahelical PQ-loop protein, termed MPU1, associated with a congenital disorder of glycosylation (47, 48) , a transport function would account for the fact that membrane disruption rescues the monosaccharide-P-dolichol utilization defect observed in intact MPU1-defective cells (49, 50) .
Interestingly, the MtN3/saliva family (Pfam no. PF03083) to which SWEET transporters belong (11) harbors an internal duplication similar to that of cystinosin (3 + 1 + 3 membrane topology), and its characteristic duplicated motif, MtN3-slv, displays some homology to the PQ loop (http://pfam.janelia.org/clan/MtN3-like) (51) . Moreover, the mitochondrial pyruvate carrier (MPC) has recently been discovered in a related family (Pfam no. PF03650) characterized by a three-helix topology and a single MtN3-like motif. This transporter is a heterooligomer formed by two members from this family, suggesting that they represent half-sized transporters. The identification of another transporter, PQLC2, in the PQ-loop protein family strengthens further this emerging view of a novel PQ-loop/MtN3/MPC superfamily of small-molecule transporters.
Finally, our study has potential implications for the study and treatment of two lysosomal storage diseases. We showed that PQLC2 transports a key chemical intermediate in cysteamine therapy of cystinosis. Moreover, PQLC2 gene silencing trapped this intermediate in patient cells, presumably in their lysosomes, when they were exposed to the drug. These data provide molecular evidence for the biochemical model of this treatment (19, 20) , and they open rationales to improve the cysteamine treatment and alleviate its constraints and side effects. For instance, allosteric or transcriptional activators of PQLC2 might potentiate cysteamine and help reduce the doses. The reason why PQLC2 knockdown exacerbates cystine storage requires further investigation. An attractive possibility is that reduction in lysosomal CAA export upregulates autophagy and, consequently, increases lysosomal proteolysis, a major source of lysosomal cystine (52) .
In another neurodegenerative lysosomal disorder, Batten disease, studies of patients' fibroblasts (53) and of a yeast model (54, 55) have reported decreased vacuolar/lysosomal CAA levels relative to WT cells. It has even been suggested that the defective protein, CLN3, or its yeast ortholog Btn1p, might transport CAAs across the lysosomal/vacuolar membrane (53, 54; cf. ref. 56) . The assignment of this molecular function to PQLC2 in mammals, and to Ypq1-3 (CAA export; this study) and Vba1-3 proteins [CAA import (33) ] in yeast, weakens this hypothesis and might help clarify the origin of these CAA abnormalities.
Materials and Methods
Reagents. L- [2,3,4- cDNA Constructs. Rat PQLC2 cDNA was amplified by PCR from a commercial clone (IRAKp961M02336Q; Imagenes). The forward primer (5′-TGAAAGCTTGCCAC-CATGGTCTGGAGGACACTG-3′) allowed inclusion of an optimized Kozak sequence. The reverse primers were 5′-AATCCGCGGGCTTGGGAGGAGCGGCTC-3′ and 5′-GGCCCGCGGGCTTGGGGCGGCCGGCTCTCGCTCTGAGGC-3′ for the WT and LL/AA constructs, respectively. PCR products were restricted with HindIII and SacII, and they were subcloned into a modified pEGFP-N1 vector (Clontech) with a valine replacing the EGFP initiation methionine (pEGFP-N1mod). cDNAs were subcloned at the SacI and NotI sites of pOX(+) vector for oocyte expression. The human CAT-1 oocyte expression plasmid (57) was a kind gift from Ellen Closs (Mainz, Germany). Capped cRNAs were synthesized from linearized plasmids using the mMessage-mMachine SP6 kit (Ambion). Yeast expression plasmids are listed in Table S1 .
Yeast Genetics. The S. cerevisiae strains used (Table S2) are derived from the Σ1278b WT (58). Cells were grown at 29°C in minimal medium buffered at pH 6.1 (59) containing glucose or galactose as a carbon source (3%) and ammonium (10 mM) as a nitrogen source. Subcellular localization of Ypq-GFP proteins was performed in cells growing exponentially in liquid glucose or galactose medium. When galactose was used as a carbon source, glucose was added (3% final concentration) for 2 h before visualizing cells so as to arrest Ypq-GFP or PQLC2-GFP neosynthesis. Labeling of the vacuolar membrane with FM4-64 was performed as described previously (60) . Cells were laid down on a thin layer of 1% agarose and viewed at room temperature with a fluorescence microscope (Eclipse E600; Nikon) equipped with a 100× differential interference contrast N.A. 1.40 Plan-Apochromat objective (Nikon) and appropriate filters. Images were captured with a digital camera (DXM1200; Nikon) and ACT-1 acquisition software (Nikon) and were processed with Photoshop CS (Adobe Systems). Galactosidase activities were measured as described previously (61) and expressed in nanomoles of o-nitrophenol per minute per milligram of protein.
Proteomic Analysis of Lysosomal Membranes. Subcellular fractions from rat liver were prepared by differential centrifugation, followed by isopycnic centrifugation of the resulting L fraction on a Nycodenz gradient (34) . The lysosome-enriched (fraction 2) and lysosome-depleted (rest of the gradient) fractions were subjected to hypoosmotic shock in 10 mM Hepes, pH 7.8, supplemented with protease inhibitors. Organelle membranes were recovered by ultracentrifugation (100,000 × g at 4°C for 1 h) and treated by chloroform/methanol extraction (62) or Triton X-114 phase separation (63) . All resulting samples were separated by SDS/PAGE and subjected to LC-MS/ MS analysis as described (64) . Database searching was carried out on the IPI_rat_decoy database (IPI_Rat v3.48). Spectral count data from lysosomeenriched or lysosome-depleted samples were merged for semiquantitative analysis of the fractions (65) , and statistical analysis was carried out according to the method of Fu et al. (35) Oocytes were prepared and injected with 50 ng of PQLC2-EGFP, PQLC2-LL/ AA-EGFP, or EGFP cRNA as described (18) . After 1 or 2 d, oocytes with high expression were selected under the epifluorescence microscope and analyzed for transport.
Radiotracer flux analysis was performed in 100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 1.8 mM CaCl 2 buffered with 5 mM Hepes, MES, or Bis-Tris propane adjusted to the required pH with NaOH or CsOH (ND100 solution). Groups of five oocytes per condition were incubated in ND100 with 0. H]His and, unless stated otherwise, 100 μM of the same nonradiolabeled compound. Incubation time was fixed to 20 min, except for saturation kinetics, where it was reduced to 10 min to preserve linearity at high substrate concentration. Uptake was stopped by two icecold ND100 washes at pH 7.0. Intracellular radioactivity was counted individually for each oocyte, after lysis in 0.1 N of NaOH, using a Tri-Carb 2100 TR liquid scintillation analyzer (Packard).
Steady-state transport currents were recorded under a two-electrode voltage-clamp using an OpusXpress 6000A workstation (Molecular Devices) and analyzed offline with Clampfit 10 software (Molecular Devices) as described (18) .
Expression and Analysis in Mammalian Cells. HeLa cells were electroporated with the PQLC2 plasmids and analyzed after 48 h by immunofluorescence as described (66) . LAMP1 was detected using the H4A3 monoclonal antibody (Developmental Studies Hybridoma Bank, University of Iowa, Ames, IA) at 0.75 mg/mL. Epifluorescence micrographs were acquired under a 100× objective lens with a Nikon Eclipse TE-2000 microscope equipped with a CCD camera (Coolsnap). Deconvolution microscopy was performed as described (66) . HEK-293 cells were transfected by lipofection and assayed for transport as described (38) .
Quantitative RT-PCR. C57Bl6 female mice (5-8 mo of age) were killed by cervical dislocation according to local and national guidelines. Tissues were immediately dissected and utilized for RNA extraction and RT using the RNeasy Mini and QuantiTect kits (Qiagen), respectively. Real-time PCR was performed with Mm_Pqlc2_1_SG and Mm_Gapdh_3_SG primers (Qiagen) and SYBR Green-based detection on a 7900HT Fast Real-Time PCR System (Applied Biosystems). The thermal cycling conditions were 95°C for 15 min, followed by 40 cycles of 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s. Expression levels were quantified by the comparative threshold cycle (C T ) method and expressed as 2 −ΔCT , where ΔC T = C T PQCL2 − C T GAPDH. For siRNA experiments on human fibroblasts, real-time PCR was performed with Hs_PQLC2_1_SG and Hs_GAPDH_2_SG primers (Qiagen) and mRNA levels were quantitated using a standard curve and Sequence Detection Systems software (Applied Biosystems).
Gene Silencing. Normal and cystinotic human skin fibroblasts [a kind gift from Corinne Antignac (Paris, France)] were cultured at 37°C in 5% CO 2 in MEM supplemented with 10% FBS. Cystinotic cells were derived from a heterozygous patient with missense (G339R) and splice site (564 + 1G > A) mutations in the CTNS gene. Cells were transfected two or three times every 2-3 d with 25 nM ON-TARGETplus reagents no. J-020760-18 (5′-GGCAGGAAGU-CAUUGGCUU; Dharmacon) or no. J-020760-19 (5′-CCAUCAACUCCGUGCUGUU; Dharmacon) or as a negative control with a luciferase-targeted siRNA (Eurofin MWG Operon) using DharmaFECT-1 (Dharmacon). To account for the possibility of a slow turnover of the PQLC2 protein, cells were plated at a density allowing growth (3-5 cell divisions) during the siRNA treatment.
Cystine and Cysteamine-Cysteine Disulfide Measurement. Two or three days after the last siRNA transfection, cells were washed with Earle's balanced salt solution (EBSS) and incubated for 2 h at 37°C in 5% CO 2 with or without cysteamine (30 μM-1 mM) in EBSS. Cells were then washed in PBS, detached with trypsin, and centrifuged at 1,000 × g for 5 min. Cell pellets were extensively washed with PBS, resuspended in 75 μL of 5.2 mM N-ethylmaleimide and deproteinized by addition of 25 μL of 12% sulfosalicylic acid. Samples were kept frozen at −80°C until analysis and centrifuged at 1,200 × g before use. After addition of a D,L-cystine-2,2′,3,3,3′,3′-d6 (C/D/N isotope) internal standard, cystine concentrations in the supernatants were determined by butylation and LC/MS/MS (API 3000 LC/MS/MS System; Applied Biosystems) as described (67) . For MxD, we designed a similar assay using deuterated cystine as an internal standard owing to the lack of commercially available deuterated MxD. A calibration curve performed with exogenous MxD (IdealP Pharma) showed that MxD butylation is linear up to at least 5 μM (Fig. S6 ). Proteins were determined on pellets using Lowry's method. Note Added in Proof During the review of our paper, a study by Liu et al. (68) reaching similar conclusions in Caenorhabditis elegans was published. ]lysine (0.1 mM) at pH 5.0, washed twice in ice-cold buffer, and subjected to scintillation counting. *P < 0.02; **P < 0.01; NS, not significant by the Student t test (n = 3). 
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